The Goldman Sachs Group Issues Pessimistic Forecast for IQVIA (NYSE:IQV) Stock Price
IQVIA (NYSE:IQV – Free Report) had its price objective trimmed by The Goldman Sachs Group from $280.00 to $250.00 in a research report released on Friday, Benzinga reports. The firm currently has a buy rating on the medical research company’s stock. IQV has been the subject of several other research reports. Royal Bank of Canada […]
More Stories
Cheniere Energy Partners (CQP) & Its Competitors Financial Analysis
Cheniere Energy Partners (NYSE:CQP – Get Free Report) is one of 23 publicly-traded companies in the “Natural gas distribution” industry,...
Xos, Inc. (NASDAQ:XOS) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Xos, Inc. (NASDAQ:XOS – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six...
Oruka Therapeutics (NASDAQ:ORKA) & Myriad Genetics (NASDAQ:MYGN) Critical Review
Myriad Genetics (NASDAQ:MYGN – Get Free Report) and Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) are both small-cap medical companies,...
AptarGroup, Inc. (NYSE:ATR) Receives $189.50 Average Target Price from Analysts
AptarGroup, Inc. (NYSE:ATR – Get Free Report) has been given an average rating of “Buy” by the seven analysts that...
Comparing VirTra (NASDAQ:VTSI) and Multi Ways (NYSE:MWG)
VirTra (NASDAQ:VTSI – Get Free Report) and Multi Ways (NYSE:MWG – Get Free Report) are both small-cap aerospace companies, but...
CAE Inc. (NYSE:CAE) Given Average Rating of “Hold” by Brokerages
CAE Inc. (NYSE:CAE – Get Free Report) (TSE:CAE) has earned an average recommendation of “Hold” from the nine brokerages that...